Association between rs1799971 polymorphism in mu opioid receptor 1 gene and susceptibility to alcohol dependence: a meta-analysis

doi:10.3969/j.issn.1004-583X.2021.04.002

Abstract

Abstract:

Objective To investigate the association between rs1799971 polymorphism in mu opioid receptor 1 (OPRM1) gene and susceptibility of alcohol dependence. Methods Through five online databases including PubMed, Web of Science, EMBASE, CNKI, and Wanfang electronic database, the studies related to the research objective were accessed, and the search deadline was on July 10, 2020. And the selected literature is based on the established inclusion criteria and exclusion criteria, and the included studies subjects is assess the quality using the Newcastle-Ottawa Scale (NOS). The data was merged by RevMan5.3 software, the allele model (A vs. G), homozygous model (AA vs. GG), heterozygous model (AG vs. GG), dominance model (AA+AG vs. GG) and recessive model (AA vs. AG+GG) P value, odds ratio (ORs) and 95% confidence interval (95% CIs) was calculated. Results A total of 22 studies with 24 independent researches were included in the meta-analysis. All eligible studies received five or more NOS scores and were in favorable quality for the included methodology. The results suggested that rs1799971 polymorphism was associated with alcohol dependence (P=0.03). Subgroup analysis indicated the association only existed in the asian population. Especially AG-genotype carriers had an increased risk of alcohol dependence. Conclusion Rs1799971 polymorphism in OPRM1 gene is significantly associated with the risk of alcohol dependence in Asians, especially AG-genotype carriers have an elevated alcohol dependence risk.

Key words: receptors, opioid, mu, polymorphism, alcohol dependence

CLC Number:

R392.11

Wang Lingli, Zhao Zhiqiang, Jin Xinrong. Association between rs1799971 polymorphism in mu opioid receptor 1 gene and susceptibility to alcohol dependence: a meta-analysis[J]. Clinical Focus, 2021, 36(4): 303-310.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.04.002

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I4/303

Figures/Tables 9

References 37

[1]	Rehm J, Allamani A, Della Vedova R, et al. General practitioners recognizing alcohol dependence: A large cross-sectional study in 6 European countries[J]. Ann Fam Med, 2015,13(1):28-32. doi: 10.1370/afm.1742 URL
[2]	Ji A, Lou P, Dong Z, et al. The prevalence of alcohol dependence and its association with hypertension: A population-based cross-sectional study4 in Xuzhou city, China[J]. BMC Public Health, 2018,18(1):364. doi: 10.1186/s12889-018-5276-1 URL
[3]	Probst C, Kilian C, Sanchez S, et al. The role of alcohol use and drinking patterns in socioeconomic inequalities in mortality: A systematic review[J]. Lancet Public Health, 2020,5(6):e324-e332. doi: 10.1016/S2468-2667(20)30052-9 URL
[4]	Kendler KS, Prescott CA, Neale MC, et al. Temperance board registration for alcohol abuse in a national sample of Swedish male twins, born 1902 to 1949[J]. Arch Gen Psychiatry, 1997,54(2):178-184. doi: 10.1001/archpsyc.1997.01830140090015 URL
[5]	Mitsuru K, Higuchi S. Genetics of alcohol dependence[J]. Psychiatry Clin Neurosci, 2011,65(3):213-225. doi: 10.1111/pcn.2011.65.issue-3 URL
[6]	Bergen AW, Kokoszka J, Peterson R, et al. Mu opioid receptor gene variants: Lack of association with alcohol dependence[J]. Mol Psychiatry, 1997,2(6):490-494. doi: 10.1038/sj.mp.4000331 URL
[7]	Ryckman K, Williams SM. Calculation and use of the Hardy-Weinberg model in association studies[M]. Curr Protoc Hum Genet, 2008, Chapter 1:Unit 1.18.
[8]	张天嵩, 钟文昭, 李博. 实用循证医学[M]. 2版. 长沙: 中南大学出版社, 2014: 305-413.
[9]	Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses[J]. BMJ, 2003,327(7414):557-560. doi: 10.1136/bmj.327.7414.557 URL
[10]	Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: A large survey[J]. CMAJ, 2007,176(8):1091-1096. pmid: 17420491
[11]	Kim SA, Kim JW, Song JY, et al. Association of polymorphisms in nicotinic acetylcholine receptor alpha 4 subunit gene (CHRNA4), mu-opioid receptor gene (OPRM1), and ethanol-metabolizing enzyme genes with alcoholism in Korean patients[J]. Alcohol, 2004,34(2-3):115-120. doi: 10.1016/j.alcohol.2004.06.004 URL
[12]	Rommelspacher H, Smolka M, Schmidt LG, et al. Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals[J]. Alcohol, 2001,24(2):129-135. pmid: 11522434
[13]	Kim SG, Kim CM, Kang DH, et al. Association of functional opioid receptor genotypes with alcohol dependence in Koreans[J]. Alcohol Clin Exp Res, 2004,28(7):986-890. doi: 10.1097/01.ALC.0000130803.62768.AB URL
[14]	Koller G, Zill P, Rujescu D, et al. Possible association between OPRM1 genetic variance at the 118 locus and alcohol dependence in a large treatment sample: Relationship to alcohol dependence symptoms[J]. Alcohol Clin Exp Res, 2012,36(7):1230-1236. doi: 10.1111/acer.2012.36.issue-7 URL
[15]	Lohel W, Fann CS, Chang YT, et al. Endogenous opioid receptor genes and alcohol dependence among Taiwanese Han[J]. Alcohol Clin Exp Res, 2004,28(1):15-19. doi: 10.1097/01.ALC.0000106303.41755.B8 URL
[16]	Miranda R, Ray L, Justus A, et al. Initial evidence of an association between OPRM1 and adolescent alcohol misuse[J]. Alcohol Clin Exp Res, 2010,34(1):112-122. doi: 10.1111/acer.2009.34.issue-1 URL
[17]	Sander T, Gscheidel N, Wendel B, et al. Human mu-opioid receptor variation and alcohol dependence[J]. Alcohol Clin Exp Res, 1998,22(9):2108-2110. pmid: 9884158
[18]	Franke P, Wang T, Nöthen MM, et al. Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence[J]. Am J Med Genet, 2001,105(1):114-119. doi: 10.1002/(ISSN)1096-8628 URL
[19]	Türkan H, Karahalil B, Kadıoˇglu E, et al. The association between the OPRM1 A118G polymorphism and addiction in a Turkish population[J]. Arh Hig Rada Toksikol, 2019,70(2):97-103. doi: 10.2478/aiht-2019-70-3153 pmid: 31246565
[20]	Park CI, Hwang SS, Kim HW, et al. Association of opioid receptor gene polymorphisms with drinking severity and impulsivity related to alcohol use disorder in a Korean population[J]. CNS Neurosci Ther, 2020,26(1):30-38. doi: 10.1111/cns.v26.1 URL
[21]	Ragia G, Veresies I, Veresie L, et al. Association study of DRD2 A2/A1, DRD3 Ser9Gly, DbetaH -1021C>T, OPRM1 A118G and GRIK1 rs2832407C>A polymorphisms with alcohol dependence[J]. Drug Metab Pers Ther, 2016,31(3):143-150.
[22]	Gegenhuber B, Weinland C, Kornhuber J, et al. OPRM1 A118G and serum beta-endorphin interact with sex and digit ratio (2D:4D) to influence risk and course of alcohol dependence[J]. Eur Neuropsychopharmacol, 2018,28(12):1418-1428. doi: S0924-977X(18)30814-9 pmid: 30322771
[23]	Zhang H, Luo X, Kranzler HR, et al. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence[J]. Hum Mol Genet, 2006,15(6):807-819. doi: 10.1093/hmg/ddl024 URL
[24]	Deb I, Chakraborty J, Gangopadhyay PK, et al. Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction[J]. J Neurochem, 2010,112(2):486-496. doi: 10.1111/jnc.2009.112.issue-2 URL
[25]	Schinka JA, Town T, Abdullah L, et al. A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances[J]. Mol Psychiatry, 2002,7(2):224-228. doi: 10.1038/sj.mp.4000951 URL
[26]	Cupic B, Stefulj J, Zapletal E, et al. Opioid system genes in alcoholism: A case-control study in Croatian population[J]. Neuropeptides, 2013,47(5):315-319. doi: 10.1016/j.npep.2013.08.002 pmid: 24035285
[27]	Nishizawa D, Han W, Hasegawa J, et al. Association of mu-opioid receptor gene polymorphism A118G with alcohol dependence in a Japanese population[J]. Neuropsychobiology, 2006,53(3):137-141. pmid: 16679777
[28]	Bart G, Kreek MJ, Ott J, et al. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden[J]. Neuropsychopharmacology, 2005,30(2):417-422. doi: 10.1038/sj.npp.1300598 URL
[29]	Konjevod M, Nikolac Perkovic M, et al. Significant association of mu-opioid receptor 1 haplotype with tobacco smoking in healthy control subjects but not in patients with schizophrenia and alcohol dependence[J]. Psychiatry Res, 2020,291:113278. doi: S0165-1781(20)31407-4 pmid: 32763540
[30]	Gürelş C, Ayhan Y, Karaaslan Ç, et al. μ-opioid receptor gene (OPRM1) polymorphisms A118G and C17T in alcohol dependence: A Turkish sample[J]. Turk Psikiyatri Derg, 2016,27(2):0.
[31]	Rouvinen-Lagerström N, Lahti J, Alho H, et al. μ-Opioid receptor gene (OPRM1) polymorphism A118G: Lack of association in Finnish populations with alcohol dependence or alcohol consumption[J]. Alcohol Alcohol, 2013,48(5):519-525. doi: 10.1093/alcalc/agt050 URL
[32]	Matthes HW, Maldonado R, Simonin F, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene[J]. Nature 1996; 383(6603):819-823. pmid: 8893006
[33]	Huang P, Chen C, Mague SD, et al. A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability[J]. Biochem J, 2012,441(1):379-386. doi: 10.1042/BJ20111050 URL
[34]	Keating GM. Nalmefene: A review of its use in the treatment of alcohol dependence[J]. CNS Drugs, 2013,27(9):761-772. doi: 10.1007/s40263-013-0101-y URL
[35]	Schacht JP, Randall PK, Latham PK, et al. Predictors of naltrexone response in a randomized trial: Reward-related brain activation, OPRM1 genotype, and smoking status[J]. Neuropsychopharmacology, 2017,42(13):2654. doi: 10.1038/npp.2017.185 pmid: 29123234
[36]	Korucuoglu O, Gladwin TE, Baas F, et al. Neural response to alcohol taste cues in youth: Effects of the OPRM1 gene[J]. Addict Biol, 2017,22(6):1562-1575. doi: 10.1111/adb.12440 pmid: 27594419
[37]	Bach P, Vollsta Dt-Klein S, Kirsch M, et al. Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: A functional imaging study in alcohol dependent subjects[J]. Eur Neuropsychopharmacol, 2015,25(8):1128-1135. doi: 10.1016/j.euroneuro.2015.04.013 URL

作者	年份	国家	种族	性别(男:女) 病例组/对照组	诊断标准	研究类型	病例组基因型(例)			对照组基因型(例)			HWE P值	NOS评分 (分)
作者	年份	国家	种族	性别(男:女) 病例组/对照组	诊断标准	研究类型	AA	AG	GG	AA	AG	GG	HWE P值	NOS评分 (分)
Bergen AW(1)^[6]	1997	美国	高加索人	未报道/未报道	DSM-Ⅲ-R	病例-对照	19	1	0	45	15	0	0.269	8
Bergen AW(2)^[6]	1997	美国	高加索人	未报道/未报道	DSM-Ⅲ-R	病例-对照	104	34	2	144	39	1	0.340	8
Bergen AW(3)^[6]	1997	美国	高加索人	未报道/未报道	DSM-Ⅲ-R	病例-对照	162	68	8	96	30	3	0.290	8
Kim SA^[11]	2004	韩国	亚洲人	127:0/185:0	DSM-Ⅳ	病例-对照	46	47	7	54	53	21	0.202	6
Rommelspacher H^[12]	2001	德国	高加索人	282:45/未报道	ICD-10	病例-对照	262	62	33	289	48	43	0.001	6
Kim SG^[13]	2004	韩国	亚洲人	106:6/80:60	DSM-Ⅳ	病例-对照	37	61	14	68	57	15	0.559	5
Koller G^[14]	2012	德国	高加索人	1403:442/ 935:928	DSM-Ⅳ	病例-对照	1461	353	31	1417	419	27	0.528	7
Loh el W^[15]	2004	中国	亚洲人	149:9/ 147:2	DSM-Ⅲ-R	病例-对照	59	77	18	70	56	22	0.061	6
Miranda R^[16]	2010	美国	高加索人	9:18/ 89:71	DSM-Ⅳ	病例-对照	13	11	3	134	22	4	0.016	8
Sander T^[17]	1998	德国	高加索人	未报道/未报道	ICD-10	病例-对照	261	62	4	289	49	2	0.961	8
Franke P^[18]	2001	德国	高加索人	未报道/未报道	DSM-Ⅲ-R	病例-对照	170	50	1	284	74	7	0.403	8
Türkan H^[19]	2019	土耳其	高加索人	87: 16/ 58:25	DSM-Ⅳ	病例-对照	25	12	0	69	14	0	0.402	6
Park CI^[20]	2020	韩国	亚洲人	314: 0/ 324:0	DSM-Ⅳ	病例-对照	125	144	43	127	142	54	0.188	7
Ragia G^[21]	2016	希腊	高加索人	72: 0/ 74:0	DSM-Ⅳ	病例-对照	55	17	0	59	15	0	0.332	6
Gegenhuber B^[22]	2018	德国	高加索人	113:87/133:107	ICD-10	病例-对照	158	40	2	185	52	3	0.760	8
Zhang H^[23]	2006	美国	高加索人	未报道/未报道	DSM-Ⅳ	病例-对照	246	68	4	256	78	4	0.014	7
Deb I^[24]	2010	印度	亚洲人	53:0/82:0	DSM-Ⅳ	病例-对照	16	32	5	44	30	8	0.397	6
Schinka JA^[25]	2002	美国	高加索人	未报道/未报道	DSM-Ⅳ	病例-对照	152	27	0	262	93	5	0.309	7
Cupic B^[26]	2013	克罗地亚	高加索人	354:0/234:0	ICD-10	病例-对照	275	75	4	266	87	4	0.288	7
Nishizawa D^[27]	2006	日本	亚洲人	50: 8/ 23:51	DSM-Ⅳ	病例-对照	12	37	15	26	33	15	0.450	6
Bart G^[28]	2005	瑞士	高加索人	281:108/82:88	DSM-Ⅲ-R	病例-对照	299	90	0	147	23	0	0.344	7
Konjevod M^[29]	2020	克罗地亚	高加索人	303:56/ 373:49	DSM-Ⅳ	病例-对照	271	84	4	323	86	13	0.019	6
Gürel? C^[30]	2016	土耳其	高加索人	124:0/118:0	DSM-Ⅳ	病例-对照	97	22	2	88	28	1	0.446	7
Rouvinen-Lagerstr?m N^[31]	2013	芬兰	高加索人	未报道/未报道	DSM-Ⅳ	队列研究	325	152	26	320	157	29	0.102	8

作者	年份	国家	种族	性别(男:女) 病例组/对照组	诊断标准	研究类型	病例组基因型(例)			对照组基因型(例)			HWE P值	NOS评分 (分)
作者	年份	国家	种族	性别(男:女) 病例组/对照组	诊断标准	研究类型	AA	AG	GG	AA	AG	GG	HWE P值	NOS评分 (分)
Bergen AW(1)^[6]	1997	美国	高加索人	未报道/未报道	DSM-Ⅲ-R	病例-对照	19	1	0	45	15	0	0.269	8
Bergen AW(2)^[6]	1997	美国	高加索人	未报道/未报道	DSM-Ⅲ-R	病例-对照	104	34	2	144	39	1	0.340	8
Bergen AW(3)^[6]	1997	美国	高加索人	未报道/未报道	DSM-Ⅲ-R	病例-对照	162	68	8	96	30	3	0.290	8
Kim SA^[11]	2004	韩国	亚洲人	127:0/185:0	DSM-Ⅳ	病例-对照	46	47	7	54	53	21	0.202	6
Rommelspacher H^[12]	2001	德国	高加索人	282:45/未报道	ICD-10	病例-对照	262	62	33	289	48	43	0.001	6
Kim SG^[13]	2004	韩国	亚洲人	106:6/80:60	DSM-Ⅳ	病例-对照	37	61	14	68	57	15	0.559	5
Koller G^[14]	2012	德国	高加索人	1403:442/ 935:928	DSM-Ⅳ	病例-对照	1461	353	31	1417	419	27	0.528	7
Loh el W^[15]	2004	中国	亚洲人	149:9/ 147:2	DSM-Ⅲ-R	病例-对照	59	77	18	70	56	22	0.061	6
Miranda R^[16]	2010	美国	高加索人	9:18/ 89:71	DSM-Ⅳ	病例-对照	13	11	3	134	22	4	0.016	8
Sander T^[17]	1998	德国	高加索人	未报道/未报道	ICD-10	病例-对照	261	62	4	289	49	2	0.961	8
Franke P^[18]	2001	德国	高加索人	未报道/未报道	DSM-Ⅲ-R	病例-对照	170	50	1	284	74	7	0.403	8
Türkan H^[19]	2019	土耳其	高加索人	87: 16/ 58:25	DSM-Ⅳ	病例-对照	25	12	0	69	14	0	0.402	6
Park CI^[20]	2020	韩国	亚洲人	314: 0/ 324:0	DSM-Ⅳ	病例-对照	125	144	43	127	142	54	0.188	7
Ragia G^[21]	2016	希腊	高加索人	72: 0/ 74:0	DSM-Ⅳ	病例-对照	55	17	0	59	15	0	0.332	6
Gegenhuber B^[22]	2018	德国	高加索人	113:87/133:107	ICD-10	病例-对照	158	40	2	185	52	3	0.760	8
Zhang H^[23]	2006	美国	高加索人	未报道/未报道	DSM-Ⅳ	病例-对照	246	68	4	256	78	4	0.014	7
Deb I^[24]	2010	印度	亚洲人	53:0/82:0	DSM-Ⅳ	病例-对照	16	32	5	44	30	8	0.397	6
Schinka JA^[25]	2002	美国	高加索人	未报道/未报道	DSM-Ⅳ	病例-对照	152	27	0	262	93	5	0.309	7
Cupic B^[26]	2013	克罗地亚	高加索人	354:0/234:0	ICD-10	病例-对照	275	75	4	266	87	4	0.288	7
Nishizawa D^[27]	2006	日本	亚洲人	50: 8/ 23:51	DSM-Ⅳ	病例-对照	12	37	15	26	33	15	0.450	6
Bart G^[28]	2005	瑞士	高加索人	281:108/82:88	DSM-Ⅲ-R	病例-对照	299	90	0	147	23	0	0.344	7
Konjevod M^[29]	2020	克罗地亚	高加索人	303:56/ 373:49	DSM-Ⅳ	病例-对照	271	84	4	323	86	13	0.019	6
Gürel? C^[30]	2016	土耳其	高加索人	124:0/118:0	DSM-Ⅳ	病例-对照	97	22	2	88	28	1	0.446	7
Rouvinen-Lagerstr?m N^[31]	2013	芬兰	高加索人	未报道/未报道	DSM-Ⅳ	队列研究	325	152	26	320	157	29	0.102	8

遗传模型	遗传关联			研究数量	异质性检验		统计模型
遗传模型	OR值	95%CI	P值	研究数量	I²(%)	P值	统计模型
总人群
A vs. G	0.93	0.82 ~ 1.05	0.24	24	65	<0.01	R
AA vs. GG	1.06	0.87 ~ 1.28	0.56	20	24	0.16	F
AG vs. GG	1.25	1.03 ~ 1.53	0.03	20	0	0.63	F
AA+AG vs. GG	1.15	0.96 ~ 1.38	0.14	20	0	0.47	F
AA vs. AG+GG	0.87	0.74 ~ 1.02	0.08	24	68	<0.01	R
亚洲人
A vs. G	0.87	0.69 ~ 1.10	0.25	6	60	0.03	R
AA vs. GG	1.03	0.76 ~ 1.39	0.85	6	46	0.10	F
AG vs. GG	1.43	1.06 ~ 1.92	0.02	6	0	0.73	F
AA+AG vs. GG	1.21	0.92 ~ 1.59	0.18	6	0	0.48	F
AA vs. AG+GG	0.69	0.48 ~ 1.01	0.06	6	64	0.02	R
高加索人
A vs. G	0.95	0.81 ~ 1.10	0.48	18	67	<0.01	R
AA vs. GG	1.08	0.84 ~ 1.39	0.55	14	17	0.55	F
AG vs. GG	1.13	0.86 ~ 1.47	0.39	14	0	0.52	F
AA+AG vs. GG	1.09	0.85 ~ 1.40	0.49	14	5	0.40	F
AA vs. AG+GG	0.93	0.78 ~ 1.11	0.43	18	67	<0.01	R
男/女性混合
A vs. G	0.89	0.76 ~ 1.05	0.17	17	72	<0.01	R
AA vs. GG	1.00	0.80 ~ 1.25	1.00	14	31	0.13	F
AG vs. GG	1.21	0.96 ~ 1.53	0.11	14	0	0.55	F
AA+AG vs. GG	1.09	0.87 ~ 1.36	0.45	14	5	0.39	F
AA vs. AG+GG	0.97	0.89 ~ 1.06	0.56	17	74	<0.01	R
男性
A vs. G	1.02	0.89 ~ 1.17	0.77	9	17	0.29	F
AA vs. GG	1.18	0.83 ~ 1.69	0.36	8	0	0.54	F
AG vs. GG	1.31	0.92 ~ 1.87	0.21	8	0	0.64	F
AA+AG vs. GG	1.26	0.90 ~ 1.77	0.17	8	0	0.65	F
AA vs. AG+GG	0.98	0.83 ~ 1.15	0.77	9	25	0.2	F

遗传模型	遗传关联			研究数量	异质性检验		统计模型
遗传模型	OR值	95%CI	P值	研究数量	I²(%)	P值	统计模型
总人群
A vs. G	0.93	0.82 ~ 1.05	0.24	24	65	<0.01	R
AA vs. GG	1.06	0.87 ~ 1.28	0.56	20	24	0.16	F
AG vs. GG	1.25	1.03 ~ 1.53	0.03	20	0	0.63	F
AA+AG vs. GG	1.15	0.96 ~ 1.38	0.14	20	0	0.47	F
AA vs. AG+GG	0.87	0.74 ~ 1.02	0.08	24	68	<0.01	R
亚洲人
A vs. G	0.87	0.69 ~ 1.10	0.25	6	60	0.03	R
AA vs. GG	1.03	0.76 ~ 1.39	0.85	6	46	0.10	F
AG vs. GG	1.43	1.06 ~ 1.92	0.02	6	0	0.73	F
AA+AG vs. GG	1.21	0.92 ~ 1.59	0.18	6	0	0.48	F
AA vs. AG+GG	0.69	0.48 ~ 1.01	0.06	6	64	0.02	R
高加索人
A vs. G	0.95	0.81 ~ 1.10	0.48	18	67	<0.01	R
AA vs. GG	1.08	0.84 ~ 1.39	0.55	14	17	0.55	F
AG vs. GG	1.13	0.86 ~ 1.47	0.39	14	0	0.52	F
AA+AG vs. GG	1.09	0.85 ~ 1.40	0.49	14	5	0.40	F
AA vs. AG+GG	0.93	0.78 ~ 1.11	0.43	18	67	<0.01	R
男/女性混合
A vs. G	0.89	0.76 ~ 1.05	0.17	17	72	<0.01	R
AA vs. GG	1.00	0.80 ~ 1.25	1.00	14	31	0.13	F
AG vs. GG	1.21	0.96 ~ 1.53	0.11	14	0	0.55	F
AA+AG vs. GG	1.09	0.87 ~ 1.36	0.45	14	5	0.39	F
AA vs. AG+GG	0.97	0.89 ~ 1.06	0.56	17	74	<0.01	R
男性
A vs. G	1.02	0.89 ~ 1.17	0.77	9	17	0.29	F
AA vs. GG	1.18	0.83 ~ 1.69	0.36	8	0	0.54	F
AG vs. GG	1.31	0.92 ~ 1.87	0.21	8	0	0.64	F
AA+AG vs. GG	1.26	0.90 ~ 1.77	0.17	8	0	0.65	F
AA vs. AG+GG	0.98	0.83 ~ 1.15	0.77	9	25	0.2	F